Dynamic and nuclear expression of PDGFRα and IGF-1R in alveolar Rhabdomyosarcoma.
Since the advent of tyrosine kinase inhibitors as targeted therapies in cancer, several receptor tyrosine kinases (RTK) have been identified as operationally important for disease progression. Rhabdomyosarcoma (RMS) is a malignancy in need of new treatment options; therefore, better understanding of the heterogeneity of RTKs would advance this goal. Here, alveolar RMS (aRMS) tumor cells derived from a transgenic mouse model expressing two such RTKs, platelet-derived growth factor (PDGFR)α and insulin-like growth factor (IGF)-1R, were investigated by fluorescence-activated cell sorting (FACS). Sorted subpopulations that were positive or negative for PDGFRα and IGF-1R dynamically altered their cell surface RTK expression profiles as early as the first cell division. Interestingly, a difference in total PDGFRα expression and nuclear IGF-1R expression was conserved in populations. Nuclear IGF-1R expression was greater than cytoplasmic IGF-1R in cells with initially high cell surface IGF-1R, and cells with high nuclear IGF-1R established tumors more efficiently in vivo. RNA interference-mediated silencing of IGF-1R in the subpopulation of cells initially harboring higher cell surface and total IGF-1R resulted in significantly reduced anchorage-independent colony formation as compared with cells with initially lower cell surface and total IGF-1R expression. Finally, in accordance with the findings observed in murine aRMS, human aRMS also had robust expression of nuclear IGF-1R.


CONCLUSIONS
RTK expression status and subcellular localization dynamics are important considerations for personalized medicine.
Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., MC-L321, Portland, OR 97239. keller@ohsu.edu.
M Imran
MI
Aslam
Simone
S
Hettmer
Jinu
J
Abraham
Dorian
D
Latocha
Anuradha
A
Soundararajan
Elaine T
ET
Huang
Martin W
MW
Goros
Joel E
JE
Michalek
Shuyu
S
Wang
Atiya
A
Mansoor
Brian J
BJ
Druker
Amy J
AJ
Wagers
Jeffrey W
JW
Tyner
Charles
C
Keller
D000818:Animals; D045744:Cell Line, Tumor; D002467:Cell Nucleus / Q000235:genetics / Q000378:metabolism*; D004195:Disease Models, Animal; D005434:Flow Cytometry; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D051379:Mice; D016513:Mice, SCID; D008822:Mice, Transgenic; D017526:Receptor, IGF Type 1 / Q000235:genetics* / Q000378:metabolism*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics* / Q000378:metabolism*; D018232:Rhabdomyosarcoma, Alveolar / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D046888:Tissue Array Analysis
D017526:Receptor, IGF Type 1; D020796:Receptor, Platelet-Derived Growth Factor alpha